CTOP (TFA)-5 mg

Description

CTOP TFA is a potent and highly selective μ-opioid receptor antagonist. CTOP TFA antagonizes the acute analgesic effect and hypermotility. CTOP TFA enhances extracellular dopamine levels in the nucleus accumbens. CTOP TFA dose-dependently enhances locomotor activity[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)–Neuroscience-Neuromodulation–C50H67N11O11S2.xC2HF3O2—-[1]Gulya K, et al. Central effects of the potent and highly selective μ opioid antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) in mice. Eur J Pharmacol. 1988 Jun 10;150(3):355-60.|[2]Badiani A, et al. Intra-VTA injections of the mu-opioid antagonist CTOP enhance locomotor activity. Brain Res. 1995 Aug 28;690(1):112-6. —-1062.27 (free base)–99.84–[{D-Phe}-CY-{D-Trp}-{Orn}T{Pen}T-NH2 (Disulfide bridge:Cys2-Pen7) (TFA salt)]–Neurological Disease–H2O : 50 mg/mL (ultrasonic)–Opioid Receptor–μ Opioid Receptor/MOR–GPCR/G Protein;Neuronal Signaling–Peptides